Can I read Nivolumab: Hyper-progressive disease: case report on EtoBox?

Nivolumab: Hyper-progressive disease: case report is a Medicine article available to read on EtoBox.

What is Nivolumab: Hyper-progressive disease: case report about?

## Hyper-progressive disease: case report A 55-year-old man developed hyper-progressive disease (HPD) during treatment with nivolumab for gastric adenocarcinoma [time to reaction onset not stated]. The man was diagnosed with gastric adenocarcinoma in July 2013. He underwent distal gastrectomy with D2 lymph node dissection for curative intent in September 2013. He received gimeracil/oteracil/ tegafur [S-1] for 1 year. In March 2016, he was found to have metastatic liver tumours, for which first-line chemotherapy with combination of received gimeracil/oteracil/ tegafur and cisplatin [SP]. After one cycle of cisplatin, the liver tumour increased and an abscess developed inside the tumour. Subsequently, percutaneous drainage was performed; however, abscess was difficult to manage. A partial liver resection was performed to control the infection in May 2016. After the liver metastasectomy, 5 cycles of gimeracil/oteracil/ tegafur monotherapy and 17 cycles of paclitaxel and ramucirumab therapy were administered for the newly emerged para-aortic and mesenteric lymph node metastases, and remaining hilar lymph node metastases. Even after paclitaxel plus ramucirumab therapy, the metastatic ly

Who reads Nivolumab: Hyper-progressive disease: case report?

Publisher

Springer Science and Business Media LLC

Published

2021

Language

EN

Field

Medicine (Health Sciences)